D-0088-2024 Class III Ongoing

Recalled by AbbVie Inc. — North Chicago, IL

FDA drug recall D-0088-2024 was initiated by AbbVie Inc. on Oct 17, 2023 and is designated Class III. Reason for recall: Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose. The recall status is ongoing. Affected quantity: 864 cartons.

Recall details

Product Type
Drugs
Report Date
Nov 15, 2023
Initiation Date
Oct 17, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
864 cartons

Product description

Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, IL 60064, U.S.A. NDC 0074-7068-11

Reason for recall

Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

Distribution pattern

Distributed in the US. No government or foreign consignees.

Code information

Lot # 1187435 exp date: 02/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0088-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0088-2024. Report a data issue: hello@regdatalab.com.